Novozymes A/S (OTCMKTS:NVZMY) Sees Large Drop in Short Interest

Novozymes A/S (OTCMKTS:NVZMY) saw a large decrease in short interest in the month of April. As of April 30th, there was short interest totaling 8,733 shares, a decrease of 92.9% from the April 15th total of 123,173 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 100,079 shares, the short-interest ratio is presently 0.1 days.

Wall Street Analyst Weigh In

A number of research firms have commented on NVZMY. Zacks Research cut Novozymes A/S from a “hold” rating to a “strong sell” rating in a report on Monday, May 4th. Rothschild & Co Redburn upgraded Novozymes A/S to a “strong-buy” rating in a research report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

Novozymes A/S Price Performance

Shares of OTCMKTS:NVZMY traded down $0.18 during midday trading on Wednesday, reaching $59.29. 45,584 shares of the company were exchanged, compared to its average volume of 94,601. The stock has a market cap of $24.58 billion, a PE ratio of 40.06, a price-to-earnings-growth ratio of 1.11 and a beta of 0.98. The business’s fifty day moving average is $58.32 and its two-hundred day moving average is $61.01. Novozymes A/S has a one year low of $49.90 and a one year high of $75.99. The company has a current ratio of 0.72, a quick ratio of 0.44 and a debt-to-equity ratio of 0.12.

Novozymes A/S (OTCMKTS:NVZMY) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.32 billion. Novozymes A/S had a net margin of 14.22% and a return on equity of 6.57%. As a group, analysts predict that Novozymes A/S will post 2.43 earnings per share for the current year.

About Novozymes A/S

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).